Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355 (n)(4)

Maha Hussain, M.D.

Committee: Oncologic Drugs Advisory Committee

Meeting Date: March 13, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to New Drug Application (NDA) 20-509, S-039, Gemzar (Gemcitabine HCl), sponsored by Eli Lilly & Company, proposed indication: for use in combination with Carboplatin for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. I am eligible to receive waivers under 18 U.S.C. §208 (b)(3) and 21 U.S.C. §355(n)(4).

Type of Interest	Nature	Magnitude
Stock	Competitor	Valued from \$25,001 to \$50,000
Stock	Competitor	Valued from \$25,001 to \$50,000

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.

//S//

Signature of SGE

___2/1/06_

Date